AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound of Formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl;

each R^a may be substituted at any substitutable position on **A** and each R^a is independently selected from the group consisting of: fluoro, chloro, bromo, NH_2, methyl, ethyl, methoxy and CF_3;

R^1 and R^2 are each independently selected from the group consisting of: C_{1-6}alkyl and C_{3-6}cycloalkyl; and

A is selected from the group consisting of:

1) 	2) 	3) 

4) 	5) 	6) 
7) 	8) 	9) 
10) 	11) 	12) 
13) 	14) 	15) 
16) 	17) 	18) 
19) 	20) 	21) 

22) 	23) 	24) 
25) 	26) 	27) 
28) 	29) 	30) 
31) 	32) 	33) 
34) 	35) 	36) 

37)  and	38) 	

wherein for 38) above R^a is substituted on **A** as shown and **Z** is selected from the group consisting of: phenyl, benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl.

2. (original) The compound according to Claim 1 wherein R^1 and R^2 are each C_{1-4}alkyl.

3. (original) The compound according to Claim 1 wherein X is $-CO_2H$.

4. (original) The compound according to Claim 1 wherein X is 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl.

5. (original) The compound according to Claim 1 wherein **A** is



6. (canceled)

7. (canceled)

8. (original) The compound according to Claim 1 wherein **A** is



9. (canceled)

10. (canceled)

11. (original) The compound according to Claim 1 wherein **A** is



and wherein the two additional R^a groups may be substituted at any substitutable position on A above.

12. (canceled)

13. (canceled)

14. (original) The compound according to Claim 1 wherein **A** is



15. (canceled)

16. (original) A compound selected from the following group:





and

or a pharmaceutically acceptable salt of any of the above.

17. (original) The compound according to Claim 1 wherein R^1 and R^2 are each methyl.

18. (original) The compound according to Claim 1 wherein R^1 is methyl and R^2 is ethyl.

19. (original) A pharmaceutical composition comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.

20. (original) A method for preventing, delaying or reversing the progression of Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 1 in amount that is effective for preventing, delaying or reversing the progression of Alzheimer's Disease.

21. (original) A method for treating Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 1 in amount that is effective for treating Alzheimer's Disease.

22. (original) A compound according to Claim 1 of Formula **I'**



I'

or a pharmaceutically acceptable salt thereof, wherein:

Z is selected from the group consisting of: phenyl, benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl,

dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl,

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl,

R^1 and R^2 are each independently ethyl or methyl, and

each R^a is independently selected from the group consisting of: fluoro, chloro, bromo, NH_2, methyl, ethyl, methoxy and CF_3.

23. (original) The compound according to Claim 22 wherein **Z** is phenyl.

24 to 28. (canceled)

29. (original) The compound according to Claim 22 of Formula **I'a**



I'a

or a pharmaceutically acceptable salt thereof, wherein:

X is $-CO_2H$, 1*H*-tetrazol-5-yl or 2*H*-tetrazol-5-yl and

R^1 and R^2 are each independently ethyl or methyl.

30. (original) A pharmaceutical composition comprising a compound according to Claim 22 in combination with a pharmaceutically acceptable carrier.

31. (original) A method for preventing, delaying or reversing the progression of Alzheimer's Disease in a patient in need thereof comprising administering to the patient a compound according to Claim 22 in amount that is effective for preventing, delaying or reversing the progression of Alzheimer's Disease.

32. (original) A method for treating Alzheimer's Disease in a patient in need thereof comprising administering to said patient a compound according to Claim 22 in amount that is effective for treating Alzheimer's Disease.